Chartwell Investment Partners LLC decreased its position in Hill-Rom Holdings, Inc. (NYSE:HRC) by 0.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 17,080 shares of the medical technology company’s stock after selling 123 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Hill-Rom were worth $1,808,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sageworth Trust Co bought a new stake in shares of Hill-Rom in the 1st quarter worth about $32,000. Financial Gravity Companies Inc. bought a new stake in shares of Hill-Rom in the 4th quarter worth about $48,000. Legacy Advisors LLC bought a new stake in shares of Hill-Rom in the 1st quarter worth about $70,000. IMS Capital Management bought a new stake in shares of Hill-Rom in the 3rd quarter worth about $71,000. Finally, Captrust Financial Advisors grew its holdings in shares of Hill-Rom by 166.3% in the 4th quarter. Captrust Financial Advisors now owns 783 shares of the medical technology company’s stock worth $69,000 after purchasing an additional 489 shares during the last quarter. 85.34% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:HRC opened at $105.56 on Tuesday. Hill-Rom Holdings, Inc. has a 12 month low of $81.82 and a 12 month high of $108.68. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.25 and a current ratio of 1.70. The stock has a market cap of $7.12 billion, a price-to-earnings ratio of 22.22, a P/E/G ratio of 1.84 and a beta of 0.95.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 22nd were given a dividend of $0.21 per share. The ex-dividend date was Thursday, March 21st. This is an increase from Hill-Rom’s previous quarterly dividend of $0.20. This represents a $0.84 dividend on an annualized basis and a yield of 0.80%. Hill-Rom’s dividend payout ratio is presently 17.68%.
A number of equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Hill-Rom from a “hold” rating to a “sell” rating in a report on Friday, March 1st. Barclays increased their price objective on shares of Hill-Rom from $103.00 to $108.00 and gave the stock an “equal weight” rating in a report on Monday. Needham & Company LLC reissued a “buy” rating and set a $116.00 price objective on shares of Hill-Rom in a report on Monday, March 11th. ValuEngine raised shares of Hill-Rom from a “hold” rating to a “buy” rating in a report on Saturday, January 19th. Finally, Morgan Stanley decreased their price objective on shares of Hill-Rom from $100.00 to $98.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $107.75.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.